Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

UCB Ventures

UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. UCB Ventures invests in innovative therapeutics and technology platforms that are early stage and higher risk, in areas adjacent to or even beyond UCB’s therapeutic focus on neurology/neurodegenerative diseases, immunology and muscular skeletal/bone health. UCB Ventures takes an active role in its portfolio companies, contributing expertise in drug discovery, development and operations. *

 

Period Start 2017-01-01 established
  Group UCB (Group)
Products Industry venture capital
  Industry 2 pharmaceutical
Person Person Whittaker, Erica (UCB 201806 VP + Head of UCB Ventures)
     
  City n. a. 
    Address record changed: 2019-02-21
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 150,000,000 (fund size (2018) 2018-06-13)
     
    * Document for �About Section�: StrideBio, Inc.. (6/13/18). "Press Release: StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform". Durham, NC.
     
   
Record changed: 2019-05-23

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for UCB (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top